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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYPro-fibrotic microenvironments of scars and tumors characterized by increased stiffness stimulate mesenchymal stromal cells (MSCs) to
express a-smooth muscle actin (a-SMA). We investigated whether incorporation of a-SMA into contractile stress fibers regulates human
MSC fate. Sorted a-SMA-positive MSCs exhibited high contractile activity, low clonogenicity, and differentiation potential limited to
osteogenesis. Knockdown of a-SMAwas sufficient to restore clonogenicity and adipogenesis inMSCs. Conversely, a-SMA overexpression
induced YAP translocation to the nucleus and reduced the high clonogenicity and adipogenic potential of a-SMA-negative MSCs.
Inhibition of YAP rescued the decreased adipogenic differentiation potential induced by a-SMA, establishing a mechanistic link between
matrix stiffness, a-SMA, YAP, andMSC differentiation. Consistent with in vitro findings, nuclear localization of YAP was positively corre-
lated in a-SMA expressing stromal cells of adiposarcoma and osteosarcoma.We propose that a-SMAmediated contraction plays a critical
role in mechanically regulating MSC fate by controlling YAP/TAZ activation.INTRODUCTION
Human mesenchymal stromal cells (MSCs) are being
used in cell therapy to support organ regeneration after
injury, e.g., by injection into the heart after myocardial
infarction (Behfar et al., 2014). However, the outcomes
of MSC therapy have been variable and the reasons for
success or failure are a matter of ongoing debate (Behfar
et al., 2014; Bianco et al., 2013). First, the potential of
MSC therapy to support organ regeneration depends on
the intrinsic character of the transplanted cell population,
which is often ill-defined (Bianco et al., 2013; Mishra
et al., 2009; Prockop et al., 2014). Second, engraftment
success, survival, phenotype, and activity of MSCs
strongly depend on the microenvironment present at
the site of delivery (Forbes and Rosenthal, 2014). This
microenvironment often shares features of a healing
wound, including inflammatory cells, neo-vasculature,
and pro-fibrotic cytokines such as TGF-b1 (Forbes and
Rosenthal, 2014). Tissue repair and tumor microenviron-
ment can convert MSCs into contractile myofibroblasts
(MFs) that de novo form a-smooth muscle actin
(a-SMA)-containing stress fibers (Hinz, 2010a; Hinz
et al., 2012). The most prominent examples are ‘‘cancer-
associated fibroblasts’’ (CAFs) which originate at least in
part from bone marrow-derived MSCs (Karnoub et al.,
2007; Mishra et al., 2009; O¨hlund et al., 2014; Quante
et al., 2011).1016 Stem Cell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The AutAcute and transient MF activation is part of the body’s
normal wound healing program, but persistent MFs
contribute to fibrosis by excessively producing and con-
tracting collagenous extracellular matrix (ECM) into stiff
scar tissue (Hinz et al., 2012). In turn, the stiffness of
mature scar promotes mechanical activation of MFs
(Hinz, 2010b). In cell therapy, MSCs engrafted into early
stages of organ fibrosis were shown to improve healing,
but delivery into stiff mature scar further enhanced fibro-
genesis in fibrotic lung, kidney, liver, and heart (Breitbach
et al., 2007; di Bonzo et al., 2008; Nagaya et al., 2005; Nini-
chuk et al., 2006; Yan et al., 2007). Substrate mechanics in
conjunction with intracellular tension have also been
shown to determine the preference of naive MSCs toward
specific lineages (Engler et al., 2006; Winer et al., 2009;
Yang et al., 2011, 2014), but the functional consequences
of MF activation (fibrogenesis) on MSC clonogenicity and
lineage differentiation potential have not been systemati-
cally investigated.
We hypothesize that acquisition of MF contractile fea-
tures, most notably expression of a-SMA, will determine
the fate of bone-marrow-derived human MSCs (hMSCs).
Our results show that a-SMA-positive hMSCs exhibit low
self-renewal and lineage differentiation potential, in
contrast to a-SMA-negative hMSCs, which are clonal and
multi-potent. Soft culture substrates that suppress the
pro-fibrotic MF phenotype also enhance the lineage differ-
entiation potential of a-SMA-positive hMSCs. We identifyhors
a-SMA incorporation into hMSC stress fibers and down-
stream translocation of YAP/TAZ transcription factors
into the nucleus as a key event in regulating genes associ-
ated with self-renewal and differentiation. Inhibition of
a-SMA may thus be a potential strategy to improve the
therapeutic potential of MSCs and reduce the risk of MSC
fibrogenesis.RESULTS
MF Activation Results in Reduced Clonogenicity and
Differentiation Potential of hMSCs
Independently of MSC origin, MF activation occurs spon-
taneously in standard cell culture on rigid tissue culture
plastic in serum-containing media. Cultured hMSCs
derived from adipose tissue, umbilical cord perivascula-
ture, and bone marrow all developed MF characteristics,
including a-SMA-positive stress fibers, extradomain-A
fibronectin (ED-A FN) in the ECM, and high contractile
activity, which were enhanced by TGF-b1 (Figure S1). To
test whether MF activation affected stem cell features,
we focused on bone-marrow derived hMSCs (Figure 1A).
In standard culture, 17% ± 4.2% of hMSCs expressed
a-SMA in F-actin-positive stress fibers, which increased
to 32% ± 5.1% after TGF-b1 treatment, associating with
3.5-fold higher contraction (Figures 1A, 1B, and S1).
TGF-b1 treatment reduced the number of colony forming
units-fibroblasts (CFU-F) by 3-fold (Figure 1B) and the abil-
ity of hMSCs to differentiate into adipogenic (10-fold) and
osteogenic (7-fold) cell lineages in conventional lineage-
induction assays supplemented with TGF-b1 (Figure 1B).
TGF-b1 treatment resulted in 1.5-fold increase in median
fluorescence intensity of common MSC markers such as
CD44, CD73, and CD90, but did not change levels of
CD105 and CD166 (Figure S2). This supports the onset of
a fibrogenic program since CD44, CD73, and CD90 have
all been identified on fibroblasts and are upregulated in
conditions of fibrosis (Ferna´ndez et al., 2013; Koumas
et al., 2003; Li et al., 2011; Maring et al., 2012; McQualter
et al., 2013).
To test whether low ECM stiffness, a powerful inhibitor
of MF activation (Goffin et al., 2006), improves hMSC
clonogenicity and lineage differentiation potential, we
cultured hMSCs on silicone substrates with different
Young’s elastic modulus simulating different scar matu-
ration stages (Figure 1C). Expression of a-SMA and ED-A
FN decreased after 5 days culture on ‘‘fibrosis-rigid’’
(65 kPa) over ‘‘wound-stiff’’ (26 kPa) to ‘‘normal tissue-
soft’’ (3 kPa) substrates (Figures 1D and 1E). With percent-
ages of a-SMA stress fiber-positive hMSCs decreasing
from 21.9% ± 3.4% (65 kPa) to 17.3% ± 2.4% (26 kPa)
and 5.7% ± 3.1% (3 kPa) (Figure 1F), the number ofStem CCFU-F increased (Figure 1G). Treatment with TGF-b1
enhanced a-SMA expression on 26 kPa and 65 kPa
substrates compared to non-treated controls, but also
reduced CFU-F capacity independently of a-SMA content
(3 kPa). This finding is consistent with previous studies
reporting inhibitory effects of TGF-b1 on mesenchymal
cell proliferation (Kim et al., 2014) and MSC self-renewal
capacity by inducing osteogenesis and chondrogenesis
(Watabe and Miyazono, 2009). Consistently, our hMSCs
exhibited 8-fold increase in the early chondrogenic
marker SOX9 and 50-fold increase of the late marker
ACAN (aggrecan) upon TGF-b1stimulation. Whereas
ACTA2 was also increased by TGF-b1 treatment in con-
ventional culture conditions (8-fold), expression levels
remained low in complete chondrogenesis medium
(containing TGF-b) and pellet culture that induced
SOX9 (7-fold) and substantially ACAN (180-fold) (Fig-
ure S1). Hence, using TGF-b1 as a stimulus is not suitable
to test whether MF activation is directing hMSC stem cell
potential.
a-SMA-Positive hMSCs Exhibit Low Clonogenicity
and Bias toward Osteogenic Potential
To answer whether loss of hMSC stem cell features on stiff
substrates is a consequence of MF activation and a-SMA
expression, we sorted a-SMA-positive and a-SMA-negative
hMSC from heterogeneous hMSC using flow cytometry
(Figure 2A). Because no cell surface marker reliably
identifies MFs, we sorted based on the observation that
a-SMA-expressing hMSCs exhibited about six times
larger spreading area than a-SMA-negative cells (Fig-
ure 2A). After live-sorting the lower and higher quartile
of hMSCs by size, the large-size-sorted fraction contained
no a-SMA-negative cells, whereas only 2.3% of the
small-sorted population were a-SMA-positive (Figure 2B).
For the remainder of this study, size-sorted hMSCs
were thus termed SMA() (small) and SMA(+) (large).
The pro-fibrotic character of SMA(+) hMSCs extended
beyond expression of a-SMA as shown by higher mRNA
levels of pro-fibrotic markers ACTA2, COL1A1, COL3A1,
CTGF, and TGFB2 as compared to SMA() hMSCs
(Figure 2C).
SMA() hMSCs contained 8-fold more CFU-Fs compared
with SMA(+) hMSCs (Figure 2D) and in single cell cloning
assays, formed 8-fold more clones than unsorted hMSCs;
SMA(+) hMSCs did not produce any clones (Figure 2D).
Consistently, mRNA levels of SOX2, OCT4, and DNMT1
genes that are indicative and instrumental for stem cell
self-renewal and clonogenicity in MSCs (Arnold et al.,
2011; Tsai et al., 2012; Yannarelli et al., 2013; Yu et al.,
2012b), were 5-fold lower in SMA(+) compared with
SMA() hMSCs (Figure 2E). When cultured under
respective lineage induction conditions, SMA() hMSCsell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The Authors 1017
Figure 1. hMSC-to-MF Activation
Reduces Clonogenicity and Lineage
Differentiation Potential
(A and B) hMSCs were cultured with and
without TGF-b1 (2 ng/ml) for 4 days to
assess MF activation by staining for a-SMA
(red) and stress fibers (F-actin, green), for
10 days to assess CFU-F formation, and
14 days to assess adipogenesis (oil-red-
O-positive lipids) and osteogenesis (Aliz-
arin Red S-positive mineralized nodules)
in respective induction media (+TGF-b1).
(B) MF activation was quantified by as-
sessing the percentage of a-SMA expressing
hMSCs. The contraction was assessed by
growing hMSC on deformable wrinkling
substrates (white lines in immunofluores-
cence image overlay) and quantifying the
total wrinkle area normalized by cell
numbers. Clonogenicity was assessed by
counting the number of colonies formed
after 10 days.
(C–G) HMSCs were cultured on FN-coated
silicone substrates, mimicking fibrosis-rigid
(65 kPa), wound-stiff (26 kPa), and normal-
tissue-soft (3 kPa) environments. (D) After
5 days, cells were analyzed by western
blotting for a-SMA and vimentin (loading
control) and (E) immunofluorescence for
a-SMA (red) and ED-A FN (green). The scale
bar represents 50 mm. (F) MF activation was
quantified as percentage of a-SMA stress
fiber positive cells. (G) Clonogenicity was
quantified in CFU-F assays on differently
stiff substrates.
All of the graphs show averages ± SD from
at least five independent experiments
(*p % 0.05, **p % 0.005, and ***p %
0.0005 using ANOVA followed by a post hoc
Tukey’s multiple comparison test). See also
Figure S1.differentiated into both lipid-producing and PPARG
transcript expressing adipocytes and osteoblasts that
expressed RUNX2 and formed mineralized nodules (Fig-
ure 2F). In contrast, SMA(+) hMSCs exhibited substantially
reduced adipogenic potential, but enhanced osteogenesis
(4- fold more mineralized nodules) (Figure 2F). Collec-
tively, these results indicate that the a-SMA-positive
fraction of hMSC populations is fibrogenic, non-clonal,
and biased toward osteogenesis.1018 Stem Cell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The AutMechanical Deactivation Restores the Differentiation
Potential of SMA(+) hMSCs
We next addressed whether expression of a-SMA in hMSCs
hallmarks reversible MF activation or terminal fibrogenic
differentiation by culturing pure SMA(+) hMSCs for
5 days on soft culture substrates. a-SMA protein levels
and sizes of cell-ECM focal adhesions decreased with
decreasing substrate stiffness (Figure S3). Cell culture on
3 kPa soft substrates resulted in 2-fold reduced expressionhors
Figure 2. Clonal and Differentiation Potentials Are Higher in Enriched a-SMA-Negative Than in a-SMA-Positive hMSC Populations
(A) hMSCs spontaneously acquire the MF phenotype, resulting in a heterogeneous population of a-SMA-positive (red) and -negative cells
(nuclei only, blue). The scale bar represents 50 mm. The cell spreading area was measured as a function of a-SMA expression.
(B) Heterogeneous hMSC populations were sorted into small (lower 25%) and large hMSCs (upper 25%) using forward scatter in FACS and
then immunostained for a-SMA in suspension or analyzed by western blotting.
(C) Small size-sorted hMSC, now defined as ‘‘SMA()’’ and large-size sorted ‘‘SMA(+)’’ hMSCs, were cultured for 1 day on stiff substrates to
assess a-SMA (red) and stress fibers (F-actin, green). Transcript levels were quantified for pro-fibrotic markers ACTA2 (a-SMA), TGFB2
(TGF-b2), COL1A1 (collagen type I), COL3A1 (collagen type III), and CTGF (CCN2) using quantitative (q)RT-PCR.
(D and E) Sorted SMA() and SMA(+) hMSCs were assessed for clonogenicity in functional CFU-F and single cell cloning assays and assessed
for (E) levels of self-renewal markers OCT4, SOX2, and DNMT1.
(F) Sorted SMA() and SMA(+) hMSCs were lineage-induced in adipogenic and osteogenic induction medium and assessed for adipogenesis
using oil red O staining and qRT-PCR analysis for PPARG and osteogenesis using Alizarin Red S staining and qRT-PCR analysis for RUNX2.
The scale bars represent (A) 50 mm and (C and F) 50 mm. The graphs show averages ± SD from at least five independent experiments
(*p% 0.05, **p% 0.005, and ***p% 0.0005 using Student’s t test). See also Figure S2.
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Figure 3. Soft Substrate Culture Restores Lineage Differentiation of SMA(+) hMSCs
(A–D) Sorted SMA(+) hMSCs were cultured on stiff and soft substrates and assessed for MF activation after 5 days, clonogenicity after
10 days, and differentiation potential after 14 days. MF activation was assessed by (B) western blotting, (C) immunofluorescence for
a-SMA (red) and stress fibers (F-actin, green) (the scale bar represents 20 mm), and (D) qRT-PCR for fibrotic markers.
(E) Self-renewal potential was quantified from CFU-F assays and qRT-PCR analysis of OCT4, SOX2, and DNMT1 transcripts.
(F) Sorted SMA(+) were grown for 5 days on stiff and soft culture substrates and then transferred to conventional culture dishes for
induction into adipogenic lineage (oil red O, PPARG) and osteogenesis (Alizarin Red S, RUNX2). The scale bar represents 50 mm.
The graphs show averages ± SD from at least five independent experiments (*p% 0.05, **p% 0.005, and ***p% 0.0005 using Student’s
t test). See also Figure S3.of a-SMA (Figures 3A and 3B), disappearance of a-SMA from
stress fibers (Figure 3C), and generally reduced levels of
fibrotic marker transcripts compared with hMSC(+) grown
on stiff substrates (Figure 3D). The culture time required to
deactivateMFsmechanically was 5 days (Figure S4). Revers-
ibility of the fibrotic phenotype was not dependent on the
degree of MF pre-activation. SMA(+) hMSCs lost the MF
phenotype on soft substrate even when being sorted from
TGF-b1-pre-treated heterogeneous populations and were1020 Stem Cell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The Autnot re-activated on soft substrate by adding TGF-b1
(Figure S4).
Transfer of SMA(+) hMSCs that had lost MF characteris-
tics on soft substrates to conventional lineage induction
media resulted in 1.3-fold higher levels of PPARG
mRNA and 10-fold increase in lipid-production than
SMA(+) hMSCs harvested from control stiff culture
(Figure 3E). Conversely, the osteogenic capacity of soft-
grown SMA(+) hMSCs was reduced by 2-fold comparedhors
to SMA(+) hMSCs from stiff cultures (Figure 3E). However,
clonogenicity and mRNA levels of OCT4, SOX2, and
DNMT1 of ‘‘MF-deactivated’’ SMA(+) hMSCs were similarly
low compared with control SMA(+) hMSCs grown on stiff
substrates (Figure 3F). Hence, SMA(+) hMSC can be deacti-
vated to lose fibrotic MF features by reducing substrate
stiffness, but do not regain clonogenicity, possibly due
to a dose-dependent effect of substrate stiffness on MF
(de)activation. To achieve greater changes in MF activation
state and to test whether the MF marker a-SMA plays
a functional role in guiding MSC fate, we next overex-
pressed and knocked down a-SMA in MF-sorted hMSC
populations.
Expression of a-SMA Directly Controls hMSC Fate
Expression of a-SMA and incorporation into stress fibers
upregulate contraction of fibroblastic cells (Hinz et al.,
2001, 2002). It is conceivable that a-SMA directly regu-
lates hMSC stem cell character because actin-myosin
generated intracellular tension guides hMSC fate decision
(Engler et al., 2006; MacQueen et al., 2013; McBeath et al.,
2004; Swift et al., 2013). To elucidate the role of a-SMA
protein in directing hMSC fate, we first transfected
SMA() hMSCs with a-SMA-GFP (Figure 4A) that localized
to stress fibers and GFP control that remained cytosolic
(Figure 4B). Expression of SMA-GFP (67 kDa) resulted
in upregulation of endogenous a-SMA (42 kDa) (Fig-
ure 4B), consistent with a positive feedback loop of
enhanced cell contraction and mechanically induced
a-SMA expression (Hinz et al., 2002). Overexpression of
a-SMA-GFP reduced the high clonogenicity of SMA()
hMSCs and transcript levels of SOX2, OCT4, and
DNMT1 by maximally 4-fold compared to GFP control
(Figure 4C). a-SMA-GFP-overexpressing SMA() hMSCs
exhibited 5-fold decreased adipogenesis (Figure 4D),
but 2-fold increased osteogenic potential compared to
controls (Figure 4D).
Next, we knocked down a-SMA in SMA(+) hMSCs using
short hairpin (sh)RNA directed against a-SMA, which
resulted in3-fold higher numbers of CFU-Fs and dramatic
upregulation of SOX2, OCT4, and DNMT1 transcripts (up
to 40-fold, OCT4) than in controls (scrambled shRNA
with GFP reporter) (Figure 4G). In cell lineage induction
assays, SMA(+) hMSCs showed 25-fold increased forma-
tion of lipid-producing adipocytes,5.6-fold higher PPARG
mRNA levels (Figure 4H), and 2.2-fold decrease of miner-
alized nodule area, as well as 100-fold decrease in RUNX2
mRNA levels after a-SMA knockdown compared with
controls (Figure 4H). Our results showing that knockdown
of a-SMA alone confers clonogenicity and adipogenic/
osteogenic differentiation suggest that the MF is an acti-
vated phenotype and not a terminal differentiation state
of SMA(+) hMSCs.Stem CExpression of a-SMA in hMSCs Controls YAP/TAZ
Nuclear Localization
We next addressed how a-SMA regulates hMSC fate and
clonogenicity. Cell contractility and actin filament bundle
assembly both stimulate activation and translocation of
YAP/TAZ to the nucleus (Dupont et al., 2011; Gaspar and
Tapon, 2014). YAP/TAZ transcriptionally regulate genes
associated with stem cell fate decision and self-renewal
(Varelas, 2014). To test whether a-SMA expression affects
YAP/TAZ localization in hMSCs, we first co-analyzed
a-SMA stress fiber intensity with the ratio of nuclear/cyto-
solic YAP on an individual cell basis and demonstrated a
clear correlation (Figure S5). The low baseline percentage
of SMA() hMSCs with predominantly nuclear YAP
(25%, nuclear/cytosolic YAP > 1) was increased to 90% after
transfection with a-SMA-GFP, corresponding to the per-
centage of SMA(+) hMSCs with constitutive nuclear YAP
(Figure 5A). Knockdown of a-SMA with shRNA reduced
the percentage of SMA(+) hMSCs with predominantly
nuclear YAP to 7% (Figure 5B).
To decipher themode of action of a-SMA, contraction, or
action polymerization, we used the a-SMA-specific fusion
peptide SMA-FP in combination with cytoskeletal drugs
(Figure 5C). SMA-FP selectively targets a-SMA in stress
fibers, inhibits a-SMA-mediated contraction, and selec-
tively depolymerizes a-SMA from stress fibers (Cle´ment
et al., 2005; Hinz et al., 2002). SMA-FP removed a-SMA
from persisting stress fibers, in contrast to control (DMSO
and skeletal actin fusion peptide, SKA-FP) SMA(+) hMSCs
(Figure S5). SMA-FP treatment resulted in low levels of
nuclear YAP and reduced hMSC contraction on wrinkling
elastomer substrates (Figure 5C). SMA(+) hMSCs treated
with the myosin II inhibitor blebbistatin showed similar
low levels of YAP in the nucleus and low contraction, but
disassembled all actins from stress fibers, as evident from
phalloidin staining (Figures 5C and S5).
Next, we stabilized stress fibers by pre-treating SMA(+)
hMSCs with jasplakinolide, followed by addition of SMA-
FP (Figure 5D). With jasplakinolide being present, the
SMA-FP was unable to depolymerize a-SMA from stress
fibers (Figure 5D) and hMSCs contraction was unaltered
(Figures 5D and 5E), indicating that the SMA-FP reduces
MF contraction primarily by depolymerizing a-SMA from
stress fibers. Whereas YAP nuclear localization remained
high under jasplakinolide/SMA-FP treatment (Figures 5D
and 5F), addition of blebbistatin to jasplakinolide-treated
SMA(+) hMSCs resulted in the loss of a-SMA from stress
fibers, reduced cell contractility, and reduced YAP nuclear
localization (Figures 5D–5F). Control SMA(+) hMSCs
treated with jasplakinolide alone were similar to untreated
cells (Figures 5D–5F). In combination, these experiments
suggest that enhanced contractile activity mediated by
a-SMA upregulates YAP/TAZ nuclear localization.ell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The Authors 1021
Figure 4. Overexpression and Knockdown of a-SMA Affecs hMSC Stem Cell Character
(A) SMA() hMSCs were transfected with control GFP or a-SMA-GFP constructs and evaluated for clonogenicity and lineage differentiation.
(B) Transfected cells were cultured for 5 days and stained for a-SMA (red) and GFP (green) (the scale bar represents 20 mm) and processed
for western blotting.
(C) The effect of a-SMA overexpression on stem cell character was assessed by CFU-F assays and qRT-PCR analysis of SOX2, OCT4, and DNMT1.
(D) Differentiation potential was tested by inducing adipogenic and osteogenic lineages using respective induction media and assessed for
adipogenesis and osteogenesis. The scale bar represents 50 mm.
(E–H) The same analysis was performed with SMA(+) hMSCs that were transfected with either scrambled (scr) shRNA or a-SMA-shRNA
constructs.
The graphs show averages ± SD from at least three independent experiments (*p % 0.05, **p % 0.005, and ***p % 0.0005 using
Student’s t test). See also Figure S4.To show that YAP/TAZ activation is indeed respon-
sible for reduced lineage differentiation and self-renewal
capacity downstream of a-SMA-expression in hMSCs, we
co-transfected SMA() hMSCs with small interfering (si)
RNA directed against YAP1 together with a-SMA-GFP.
Transfection of YAP1 siRNA substantially reduced YAP
expression levels (Figure 6A) and resulted in reduced
RUNX2mRNA levels, increased PPARGmRNA, and reduced1022 Stem Cell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The AutSOX2 and OCT4 levels in control cells (Figure 6A, GFP).
Knockdown of YAP1 in a-SMA-overexpressing hMSCs
restored expression of PPARGmRNA and strongly reduced
RUNX2 mRNA expression (Figure 6A). These results
confirmed that the effect of high a-SMA expression on
hMSC lineage differentiation potential is mediated by
YAP. However, knockdown of YAP1 in a-SMA-overexpress-
ing hMSCs did not restore high expression of SOX2 andhors
Figure 5. Presence of a-SMA in hMSC Stress Fibers Results in YAP/TAZ Nuclear Accumulation
(A) Sorted SMA() hMSCs were transfected with control GFP and a-SMA-GFP constructs.
(B) Sorted SMA(+) hMSCs were transfected with control scrambled (scr) and a-SMA-shRNA constructs. Localization of YAP/TAZ was
visualized using immunofluorescence staining for YAP (red) and GFP (green).
(C–F) The ratio of nuclear over cytosolic YAP/TAZ was calculated by image analysis and the percentage of cells with predominantly nuclear
YAP/TAZ localization was determined. Sorted SMA(+) cells were either pre-treated with (C) DMSO (control) or (D) jasplakinolide for 30 min,
followed by the addition of the a-SMA N-terminal peptide AcEEED (SMA-FP), blebbistatin, or DMSO control for another 40 min. Cells were
then stained for YAP and a-SMA or YAP and stress fibers as indicated and assessed for contraction using wrinkling silicone substrates.
Quantified from these images were (E) cell contraction as percentage of cells associated with wrinkles, and (F) percentage of cells with
predominant nuclear YAP/TAZ localization.
All scale bars represent 20 mm. The graphs show averages ± SD from at least three independent experiments (*p% 0.05 and **p% 0.005
using ANOVA followed by a post hoc Tukey’s multiple comparison test). See also Figure S5.
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Figure 6. Suppression of MSC Adipogenesis by a-SMA Is Mediated via YAP
(A) Sorted SMA() hMSCs were co-transfected with siRNA directed against YAP1 together with control GFP or a-SMA-GFP constructs and
assessed after 5 days. YAP downregulation was confirmed using western blotting.
(B) Sorted SMA() hMSCs were transfected with control GFP or a-SMA-GFP constructs and treated for 5 days with verteporfin (VP, 2 mM) or
DMSO control. Efficacy of vereporfin was assessed by performing qRT-PCR for the YAP1 downstream target CCN2 (CTGF). All cells were
analyzed by qRT-PCR for mRNA expression of RUNX2, PPARG, SOX2, and OCT4.
The graphs show averages ± SD from three different donors per condition (*p% 0.05, **p% 0.005, and ***p% 0.0005 using ANOVA
followed by a post hoc Tukey’s multiple comparison test).OCT4, as expected if a-SMA would suppress hMSC self-
renewal by acting through YAP1 (Figure 6A). To test
whether this result was due to the overall loss of YAP, we
used verteporfin to selectively abrogate the nuclear activity
of YAP by inhibiting binding to TEAD elements (Liu-Chit-
tenden et al., 2012) (Figure 6B). Drug action was controlled
by low levels of the YAP1 downstream target CCN2 (CTGF)
(Figure 6B). Treating SMA() and SMA()-overexpressing
a-SMA with verteporfin generally confirmed our results
obtained with YAP1 knockdown (Figure 6B). Hence,
a-SMA expression levels regulate the hMSC multilineage
differentiation program via YAP, but downregulate hMSC
self-renewal possibly through a different mechanism.
Finally, to investigate whether a-SMA expression is
relevant for YAP/TAZ activation andhMSC lineage determi-
nation in vivo, we correlated a-SMA expression and YAP1024 Stem Cell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The Autnuclear localization in soft mesenchymal tumors (adipo-
sarcoma) and stiff mesenchymal tumors (osteosarcoma)
that involve MSC tumorigenesis and fibrogenesis (Moh-
seny et al., 2009; Rodriguez et al., 2012; Xiao et al., 2013).
The levels of a-SMA expression were negligible in healthy
fat control tissue and low in normal bone, but significantly
higher in the activated stroma of the respective tumor (Fig-
ures 7A–7C). Increased a-SMA expression in adiposarcoma
correlated with 3.5-fold higher percentages of cells with
predominantly nuclear YAP staining (22%) compared to
normal fat tissue (6%, Figures 7A, 7C, and 7D). The levels
of nuclear localized YAP staining did not significantly in-
crease in osteosarcoma compared to already high levels
observed in healthy bone (Figures 7B–7D), supporting
that high levels of YAP/TAZ in mesenchymal cells direct
osteogenic differentiation.hors
Figure 7. Expression of a-SMA Correlates
with High Levels of Nuclear YAP/TAZ in
Human Adiposarcoma and Osteosarcoma
Tissues
(A) Human normal fat and adiposarcoma
tissue samples were obtained from the same
donor, sectioned, and stained for a-SMA
(red), YAP (green), and cell nuclei (blue).
(B) Donor-matched normal bone and oste-
osarcoma tissue were similarly processed.
(C and D) Percentage of (C) a-SMA-positive
cells and (D) cells with predominantly nu-
clear YAP were quantified from at least three
tissue sections per donor. The graphs show
averages ± SD from three different donors
per condition (*p % 0.05, **p % 0.005,
and ***p% 0.0005 using ANOVA followed
by a post hoc Tukey’s multiple comparison
test).DISCUSSION
MSCs are prone to MF activation by stiff ECM and TGF-b1,
but the consequences on their stem cell potential and
reversibility have not been systematically assessed. We
establish a direct link between a-SMA expression/function,
YAP/TAZ activity, and hMSC fate. Different actin isoforms
promote specific types of actin organization levels and a
shift in the ratios of actin isoforms can reprogram cell
differentiation (Lechuga et al., 2014; Tondeleir et al.,
2012). a-SMA incorporation into existing stress fibers has
been shown to increase actin organization and intracellular
tension (Goffin et al., 2006; Hinz et al., 2001). Actin organi-
zation as cortical filaments or incorporation into stress fiber
bundles has been shown to differentially control YAP/TAZ
activation, nuclear localization, and regulation of the
Hippo pathway (Gaspar and Tapon, 2014; Halder et al.,
2012; Yu et al., 2012a). In epithelia, cell-morphology-
dependent actin organization provides positional informa-
tion to individual cells in a multicellular layer (Aragona
et al., 2013; Wada et al., 2011). YAP/TAZ are also centralStem Cin regulating cell fate decision by interacting with RUNX2
and PPARG (Hong et al., 2005; Hong and Yaffe, 2006; Vare-
las et al., 2008). Consistently, neo-expression of a-SMA
alone was sufficient in our experiments to reduce hMSC
differentiation potential, which was rescued by inhibition
and downregulation of YAP1.
Whether the a-SMA-induced nuclear shift of YAP is
responsible for reduced clonogenicity is unclear because
YAP1 knockdown did not protect against the reduction of
SOX2 and OCT4 transcript levels upon a-SMA-overexpres-
sion. Consistently, YAP binds to and is expected to activate
gene transcription of SOX2 and OCT4 in embryonic stem
(ES) cells (Lian et al., 2010). However, YAP is inactivated
in ES cells during differentiation (Lian et al., 2010), whereas
it drives specific lineage specification in MSCs (Dupont
et al., 2011). Overexpression of OCT4 has been shown to
result in increased MSC proliferation, whereas OCT4
knockdown had the opposite effect (Tsai et al., 2012).
Similarly, knockdown of SOX2 reduces proliferation in
MSC-derived osteoprogenitors that is restored by YAP1
overexpression, which acts downstream of SOX2 in thisell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The Authors 1025
model (Seo et al., 2013). Hence, the interplay between
a-SMA, YAP/TAZ, and self-renewal genes is complex and
not entirely understood at present.
YAP/TAZ transcription factors provide a direct link
between cell mechanosensing and gene regulation (Halder
et al., 2012). Inhibition of cell contraction has been shown
to decrease nuclear localization of YAP/TAZ and transcrip-
tion of downstream genes, whereas high intracellular
tension drives YAP/TAZ into the nucleus (Calvo et al.,
2013; Dupont et al., 2011). Expression of a-SMA is not
essential for the localization of YAP/TAZ in the nucleus
and 10% of the hMSC retained predominantly nuclear
YAP even in the presence of the SMA-FP. However, incorpo-
ration of a-SMA into existing stress fibers substantially in-
creases contractile force and cell stress (Hinz et al., 2001)
and thus accentuates fibrogenic transcription programs.
YAP/TAZ have been shown to be involved in regulating
a-SMA expression and fibrogenesis using an experimental
model of epithelial-to-mesenchymal transition (Speight
et al., 2013) and during lung fibroblast-to-MF activation
by stiff ECM (Liu et al., 2015). These reports and our works
suggest a positive feedback loop between a-SMA and YAP/
TAZ signaling that amplifies fibrosis.
Importantly, expression of a-SMA is not simply a marker
for MF activation, but also the driver of cell function and
fate. Increased expression of a-SMA directly reduces the
clonal potential of hMSCs and guides their differentiation
toward osteoblasts. Hence, a-SMAnot only identifies osteo-
progenitors in hMSC populations as shown by others
before (Grcevic et al., 2012; Kalajzic et al., 2008), but may
be part of the mechanism driving differentiation. Analysis
of bone marrow-derived hMSCs treated with TGF-b1 and/
or exposed to fibrosis-stiff culture substrates has previously
revealed a fibrogenic MF activation program (Park et al.,
2011; Wang et al., 2004). Our results additionally demon-
strate that neo-expression of a-SMA associates with
reduced clonogenicity and lineage differentiation potential
of hMSCs and that this program is reversible. SMA(+)
hMSC can be deactivated to lose fibrotic MF features by
reducing substrate stiffness. Originally considered to be a
terminal differentiation state of various precursor cells,
deactivation of the MF has been shown in recent experi-
mental models of kidney and liver fibrosis (Hecker et al.,
2011; Kisseleva and Brenner, 2013). In vitro, the depletion
of MF features in fibroblasts and MSCs is achieved by cul-
ture on soft silicone substrates (Achterberg et al., 2014;
Balestrini et al., 2012; Goffin et al., 2006; Park et al.,
2011) or by treatment with anti-fibrotic growth factors
(Desai et al., 2014). Our results add to these findings that
SMA(+) hMSC populations, deactivated to loseMF features,
regain adipogenic lineage differentiation potential rather
than turning into a-SMA-negative fibroblasts. Hence,
a-SMA-positive cells are likely derived from previously1026 Stem Cell Reports j Vol. 4 j 1016–1030 j June 9, 2015 j ª2015 The Auta-SMA-negative hMSCs and expression of a-SMA reversibly
reduced their clonogenicity and lineage potential.
Our findings have important implications for hMSC ther-
apy in fibroproliferative diseases, including tumor forma-
tion and development of fibrosis. Our in vivo data show
that the percentage of a-SMA-expressing MFs in sarcomas
correlates with the degree of YAP/TAZ activation. A wide
variety of different tumors have been shown to accumulate
stromal cells that are positive for a-SMA and perform MF
functions, including stiffeningof the stromaandpromoting
tumor progression (Hinz et al., 2012; O¨hlund et al., 2014).
Consistently, YAP expressed in cancer-associated fibroblasts
was recently shown to play an important role in controlling
of cytoskeleton-regulating genes, as well as tumor cell inva-
sion and ECM stiffening (Calvo et al., 2013). We propose a
feedforward loop of MSC-to-MF activation in the tumor
microenvironment, leading to higher contractile cells and
stiffer ECM, which both lead to increased YAP/TAZ activity
and conversion of regenerative MSCs into fibrotic MFs.
Interrupting this feedforward loop will have important
consequences for hMSC potential in clinical applications.
First, specific inhibitors of a-SMA such as the SMA-FP or
shRNA strategies may be co-delivered with hMSCs to exert
fibrosis-inhibitory effects on the resident fibrotic cell
population in the lesion. Second, suppressing MSC-to-MF
activation during cell culture expansion will enhance the
fraction of valuable stem cells and reduce the risk of fibrosis
upon implantation. We have shown that explantation
and continued culture on soft culture substrates renders
populations of lung fibroblasts resistant to subsequent
mechanical activation on stiff substrates over several
consecutive passages (Balestrini et al., 2012). This concept
of cells acquiring a ‘‘mechanical memory’’ has recently
been confirmed for MSC lineage programs on a shorter
timescale with YAP/TAZ being involved (Yang et al.,
2014). It is yet unclear whyhMSCs and othermesenchymal
cells that have been cultured on conventional stiff culture
dishes are not similarly primed and can at least acutely
(up to 8 days in our experiments) lose fibrogenic character
upon short-term exposure (5 days) to soft substrates. In our
own studies, we found it to be essential to use substrates
with a pathophysiological stiffness range (1–100 kPa) and
to never expose cells to tissue culture plastic formechanical
priming to occur (Balestrini et al., 2012).EXPERIMENTAL PROCEDURES
For detailed experimental procedures, see the Supplemental Exper-
imental Procedures.
Tissue, Cell Culture, and Drugs
MSCswere obtained from the bonemarrow of healthy donors (Da-
vies et al., 2001), fromumbilical perivasculature (Ennis et al., 2008)hors
and from adipose tissue (Vermette et al., 2007). Tissue sections of
mesenchymal tumors and respective healthy control tissues were
purchased fromBiomax.Cell drugs used in these study are: blebbis-
tatin (50 mM) (Tocris Bioscience, Cedarlane), jasplakinolide
(50 nM) (Life Technologies), verteporfin (2 mM) (Sigma-Aldrich),
SMA-FP and control SKA-FP (5 mM). Immunofluorescence, micro-
scopy, and western blot were performed as described earlier with
antibodies listed in the Supplemental Experimental Procedures
(Klingberg et al., 2014). Adipogenesis, osteogenesis, and chondro-
genesis were induced and assessed as described earlier (Majd et al.,
2011). Elastic silicone culture substrates were purchased from
Excellness Biotech SA and activated for cell adhesion by plasma
oxygenation (PE-100, Plasma Etch), followed by coating with
2 mg/cm2 FN (Millipore). Cell contractility was assessed using
FN-coated wrinkling silicone substrates (Balestrini et al., 2012).
Flow Cytometry and Cell Sorting
For flow cytometry, fixed cells were immunostained using
antibodies CD44-APC-H7, CD73-PE-CY7, CD90-FITC, CD105-
PerCP-Cy5.5, CD146-V450, and respective isotype controls (BD
Bioscience) and analyzed using a flow cytometer (LSR II, BD). To
enrich for a-SMA-positive and a-SMA-negative hMSC populations,
cells were trypsinized and sorted for cell size (upper and lower 25%
in forward scatter) using fluorescence activated cell sorting (FACS)
(FACSAria III, BD).
Plasmid Constructs
a-SMA was overexpressed using a-SMA-GFP (Cle´ment et al., 2005)
and knockeddown using 29-mer shRNA targeting a-SMA tran-
scripts in pGFP-V-RS vectors (OriGene Technologies). Human
YAP1 27-mer siRNA were ordered from (OriGene Technologies).
Cells were transfected using an electroporation device (Neon,
Life Technologies).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and five figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2015.05.004.
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